nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—Epirubicin—liver cancer	0.294	0.401	CbGbCtD
Tapentadol—UGT1A9—Sorafenib—liver cancer	0.272	0.371	CbGbCtD
Tapentadol—CYP2C19—Sorafenib—liver cancer	0.0547	0.0746	CbGbCtD
Tapentadol—CYP2C9—Sorafenib—liver cancer	0.0455	0.062	CbGbCtD
Tapentadol—CYP2D6—Sorafenib—liver cancer	0.0416	0.0567	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—liver cancer	0.0253	0.0344	CbGbCtD
Tapentadol—Drug interaction—Sorafenib—liver cancer	0.00224	0.0218	CcSEcCtD
Tapentadol—Drug hypersensitivity—Epirubicin—liver cancer	0.0019	0.0185	CcSEcCtD
Tapentadol—Drug hypersensitivity—Doxorubicin—liver cancer	0.00176	0.0171	CcSEcCtD
Tapentadol—Breast disorder—Sorafenib—liver cancer	0.00136	0.0132	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00136	0.0132	CcSEcCtD
Tapentadol—Nasopharyngitis—Sorafenib—liver cancer	0.00135	0.0131	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00133	0.0129	CcSEcCtD
Tapentadol—Abdominal discomfort—Sorafenib—liver cancer	0.00125	0.0121	CcSEcCtD
Tapentadol—Erectile dysfunction—Sorafenib—liver cancer	0.0012	0.0117	CcSEcCtD
Tapentadol—Weight decreased—Sorafenib—liver cancer	0.00118	0.0115	CcSEcCtD
Tapentadol—Infestation NOS—Sorafenib—liver cancer	0.00116	0.0113	CcSEcCtD
Tapentadol—Infestation—Sorafenib—liver cancer	0.00116	0.0113	CcSEcCtD
Tapentadol—Lung disorder—Epirubicin—liver cancer	0.00108	0.0105	CcSEcCtD
Tapentadol—Urinary tract disorder—Sorafenib—liver cancer	0.00103	0.01	CcSEcCtD
Tapentadol—Connective tissue disorder—Sorafenib—liver cancer	0.00102	0.00996	CcSEcCtD
Tapentadol—Urethral disorder—Sorafenib—liver cancer	0.00102	0.00994	CcSEcCtD
Tapentadol—Lung disorder—Doxorubicin—liver cancer	0.001	0.00975	CcSEcCtD
Tapentadol—Feeling hot—Epirubicin—liver cancer	0.000976	0.00951	CcSEcCtD
Tapentadol—Cardiac disorder—Sorafenib—liver cancer	0.000966	0.00941	CcSEcCtD
Tapentadol—Angiopathy—Sorafenib—liver cancer	0.000945	0.0092	CcSEcCtD
Tapentadol—Immune system disorder—Sorafenib—liver cancer	0.00094	0.00916	CcSEcCtD
Tapentadol—Mediastinal disorder—Sorafenib—liver cancer	0.000938	0.00914	CcSEcCtD
Tapentadol—Mental disorder—Sorafenib—liver cancer	0.000912	0.00888	CcSEcCtD
Tapentadol—Malnutrition—Sorafenib—liver cancer	0.000906	0.00883	CcSEcCtD
Tapentadol—Feeling hot—Doxorubicin—liver cancer	0.000903	0.0088	CcSEcCtD
Tapentadol—Thinking abnormal—Epirubicin—liver cancer	0.000837	0.00815	CcSEcCtD
Tapentadol—Angioedema—Sorafenib—liver cancer	0.000828	0.00806	CcSEcCtD
Tapentadol—Syncope—Sorafenib—liver cancer	0.000813	0.00791	CcSEcCtD
Tapentadol—Dysarthria—Epirubicin—liver cancer	0.00081	0.00789	CcSEcCtD
Tapentadol—Loss of consciousness—Sorafenib—liver cancer	0.000797	0.00776	CcSEcCtD
Tapentadol—Cough—Sorafenib—liver cancer	0.000791	0.0077	CcSEcCtD
Tapentadol—Coordination abnormal—Epirubicin—liver cancer	0.00078	0.0076	CcSEcCtD
Tapentadol—Thinking abnormal—Doxorubicin—liver cancer	0.000774	0.00754	CcSEcCtD
Tapentadol—Arthralgia—Sorafenib—liver cancer	0.000772	0.00751	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000766	0.00746	CcSEcCtD
Tapentadol—Abnormal dreams—Epirubicin—liver cancer	0.000757	0.00737	CcSEcCtD
Tapentadol—Dry mouth—Sorafenib—liver cancer	0.000755	0.00735	CcSEcCtD
Tapentadol—Dysarthria—Doxorubicin—liver cancer	0.00075	0.0073	CcSEcCtD
Tapentadol—Anaphylactic shock—Sorafenib—liver cancer	0.00074	0.0072	CcSEcCtD
Tapentadol—Infection—Sorafenib—liver cancer	0.000735	0.00716	CcSEcCtD
Tapentadol—Shock—Sorafenib—liver cancer	0.000728	0.00709	CcSEcCtD
Tapentadol—Nervous system disorder—Sorafenib—liver cancer	0.000725	0.00706	CcSEcCtD
Tapentadol—Coordination abnormal—Doxorubicin—liver cancer	0.000722	0.00703	CcSEcCtD
Tapentadol—Skin disorder—Sorafenib—liver cancer	0.000719	0.007	CcSEcCtD
Tapentadol—Abnormal dreams—Doxorubicin—liver cancer	0.000701	0.00682	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000674	0.00656	CcSEcCtD
Tapentadol—Mental disability—Epirubicin—liver cancer	0.000665	0.00647	CcSEcCtD
Tapentadol—Dyspnoea—Sorafenib—liver cancer	0.00066	0.00642	CcSEcCtD
Tapentadol—Dyspepsia—Sorafenib—liver cancer	0.000651	0.00634	CcSEcCtD
Tapentadol—Decreased appetite—Sorafenib—liver cancer	0.000643	0.00626	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Sorafenib—liver cancer	0.000639	0.00622	CcSEcCtD
Tapentadol—Fatigue—Sorafenib—liver cancer	0.000638	0.00621	CcSEcCtD
Tapentadol—Constipation—Sorafenib—liver cancer	0.000633	0.00616	CcSEcCtD
Tapentadol—Mental disability—Doxorubicin—liver cancer	0.000615	0.00599	CcSEcCtD
Tapentadol—Hot flush—Epirubicin—liver cancer	0.000595	0.00579	CcSEcCtD
Tapentadol—Menopausal symptoms—Epirubicin—liver cancer	0.000589	0.00574	CcSEcCtD
Tapentadol—Urticaria—Sorafenib—liver cancer	0.000588	0.00572	CcSEcCtD
Tapentadol—Lethargy—Epirubicin—liver cancer	0.000568	0.00553	CcSEcCtD
Tapentadol—Osteoarthritis—Epirubicin—liver cancer	0.000556	0.00542	CcSEcCtD
Tapentadol—Hot flush—Doxorubicin—liver cancer	0.00055	0.00536	CcSEcCtD
Tapentadol—Menopausal symptoms—Doxorubicin—liver cancer	0.000545	0.00531	CcSEcCtD
Tapentadol—Hypersensitivity—Sorafenib—liver cancer	0.000545	0.00531	CcSEcCtD
Tapentadol—Asthenia—Sorafenib—liver cancer	0.000531	0.00517	CcSEcCtD
Tapentadol—Lethargy—Doxorubicin—liver cancer	0.000525	0.00511	CcSEcCtD
Tapentadol—Pruritus—Sorafenib—liver cancer	0.000523	0.0051	CcSEcCtD
Tapentadol—Ataxia—Epirubicin—liver cancer	0.000523	0.00509	CcSEcCtD
Tapentadol—Osteoarthritis—Doxorubicin—liver cancer	0.000515	0.00501	CcSEcCtD
Tapentadol—Diarrhoea—Sorafenib—liver cancer	0.000506	0.00493	CcSEcCtD
Tapentadol—Breast disorder—Epirubicin—liver cancer	0.000503	0.00489	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000501	0.00488	CcSEcCtD
Tapentadol—Nasopharyngitis—Epirubicin—liver cancer	0.000497	0.00484	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000491	0.00478	CcSEcCtD
Tapentadol—Dizziness—Sorafenib—liver cancer	0.000489	0.00476	CcSEcCtD
Tapentadol—Ataxia—Doxorubicin—liver cancer	0.000484	0.00471	CcSEcCtD
Tapentadol—Vomiting—Sorafenib—liver cancer	0.00047	0.00458	CcSEcCtD
Tapentadol—Rash—Sorafenib—liver cancer	0.000466	0.00454	CcSEcCtD
Tapentadol—Dermatitis—Sorafenib—liver cancer	0.000466	0.00454	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—liver cancer	0.000465	0.00453	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000463	0.00451	CcSEcCtD
Tapentadol—Headache—Sorafenib—liver cancer	0.000463	0.00451	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—liver cancer	0.00046	0.00448	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000454	0.00442	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Epirubicin—liver cancer	0.000447	0.00435	CcSEcCtD
Tapentadol—Pollakiuria—Epirubicin—liver cancer	0.000444	0.00432	CcSEcCtD
Tapentadol—Nausea—Sorafenib—liver cancer	0.000439	0.00428	CcSEcCtD
Tapentadol—Weight decreased—Epirubicin—liver cancer	0.000435	0.00423	CcSEcCtD
Tapentadol—Infestation—Epirubicin—liver cancer	0.000429	0.00417	CcSEcCtD
Tapentadol—Infestation NOS—Epirubicin—liver cancer	0.000429	0.00417	CcSEcCtD
Tapentadol—Urinary tract infection—Epirubicin—liver cancer	0.000417	0.00406	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000413	0.00403	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—liver cancer	0.000411	0.004	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—liver cancer	0.000402	0.00392	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—liver cancer	0.000397	0.00386	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—liver cancer	0.000397	0.00386	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—liver cancer	0.000392	0.00381	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—liver cancer	0.000386	0.00375	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—liver cancer	0.000383	0.00373	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—liver cancer	0.00038	0.0037	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—liver cancer	0.000378	0.00368	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—liver cancer	0.000377	0.00367	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—liver cancer	0.000371	0.00361	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—liver cancer	0.000362	0.00353	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—liver cancer	0.00036	0.0035	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—liver cancer	0.000357	0.00348	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—liver cancer	0.000354	0.00345	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—liver cancer	0.000352	0.00342	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—liver cancer	0.00035	0.00341	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—liver cancer	0.000349	0.0034	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—liver cancer	0.000349	0.0034	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—liver cancer	0.000348	0.00338	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—liver cancer	0.000347	0.00338	CcSEcCtD
Tapentadol—Chills—Epirubicin—liver cancer	0.000345	0.00336	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—liver cancer	0.000343	0.00334	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—liver cancer	0.000337	0.00328	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—liver cancer	0.000335	0.00326	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—liver cancer	0.000333	0.00324	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—liver cancer	0.00033	0.00322	CcSEcCtD
Tapentadol—Tension—Epirubicin—liver cancer	0.000329	0.0032	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—liver cancer	0.000325	0.00317	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—liver cancer	0.000323	0.00315	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—liver cancer	0.000322	0.00313	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—liver cancer	0.000321	0.00312	CcSEcCtD
Tapentadol—Chills—Doxorubicin—liver cancer	0.000319	0.00311	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—liver cancer	0.000316	0.00307	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—liver cancer	0.000312	0.00304	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—liver cancer	0.00031	0.00302	CcSEcCtD
Tapentadol—Agitation—Epirubicin—liver cancer	0.000308	0.003	CcSEcCtD
Tapentadol—Tension—Doxorubicin—liver cancer	0.000304	0.00296	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—liver cancer	0.000301	0.00293	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—liver cancer	0.000301	0.00293	CcSEcCtD
Tapentadol—Syncope—Epirubicin—liver cancer	0.0003	0.00292	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—liver cancer	0.000296	0.00288	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—liver cancer	0.000294	0.00287	CcSEcCtD
Tapentadol—Cough—Epirubicin—liver cancer	0.000292	0.00285	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—liver cancer	0.000292	0.00284	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—liver cancer	0.00029	0.00283	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—liver cancer	0.000285	0.00278	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—liver cancer	0.000285	0.00277	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—liver cancer	0.000284	0.00277	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000283	0.00276	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—liver cancer	0.000279	0.00272	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—liver cancer	0.000278	0.00271	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—liver cancer	0.000278	0.00271	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—liver cancer	0.000276	0.00268	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—liver cancer	0.000274	0.00267	CcSEcCtD
Tapentadol—Oedema—Epirubicin—liver cancer	0.000273	0.00266	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—liver cancer	0.000273	0.00266	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—liver cancer	0.000272	0.00265	CcSEcCtD
Tapentadol—Infection—Epirubicin—liver cancer	0.000272	0.00264	CcSEcCtD
Tapentadol—Cough—Doxorubicin—liver cancer	0.00027	0.00263	CcSEcCtD
Tapentadol—Shock—Epirubicin—liver cancer	0.000269	0.00262	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—liver cancer	0.000269	0.00261	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—liver cancer	0.000268	0.00261	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—liver cancer	0.000267	0.0026	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—liver cancer	0.000266	0.00259	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—liver cancer	0.000264	0.00257	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—liver cancer	0.000264	0.00257	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—liver cancer	0.000263	0.00256	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000262	0.00255	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—liver cancer	0.000258	0.00251	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—liver cancer	0.000255	0.00249	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—liver cancer	0.000255	0.00248	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—liver cancer	0.000253	0.00246	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—liver cancer	0.000253	0.00246	CcSEcCtD
Tapentadol—Infection—Doxorubicin—liver cancer	0.000251	0.00245	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000249	0.00243	CcSEcCtD
Tapentadol—Shock—Doxorubicin—liver cancer	0.000249	0.00242	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—liver cancer	0.000248	0.00242	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—liver cancer	0.000247	0.00241	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—liver cancer	0.000247	0.0024	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—liver cancer	0.000246	0.00239	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—liver cancer	0.000245	0.00239	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—liver cancer	0.000245	0.00238	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—liver cancer	0.000244	0.00237	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—liver cancer	0.000243	0.00237	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—liver cancer	0.000241	0.00234	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—liver cancer	0.000238	0.00231	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—liver cancer	0.000236	0.0023	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—liver cancer	0.000236	0.0023	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—liver cancer	0.000236	0.00229	CcSEcCtD
Tapentadol—Constipation—Epirubicin—liver cancer	0.000234	0.00228	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00023	0.00224	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—liver cancer	0.000229	0.00223	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—liver cancer	0.000227	0.00221	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—liver cancer	0.000226	0.0022	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—liver cancer	0.000225	0.00219	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—liver cancer	0.000225	0.00219	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—liver cancer	0.000223	0.00217	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—liver cancer	0.00022	0.00214	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000218	0.00213	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—liver cancer	0.000218	0.00212	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—liver cancer	0.000217	0.00211	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—liver cancer	0.000216	0.00211	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—liver cancer	0.000208	0.00203	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—liver cancer	0.000201	0.00196	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—liver cancer	0.000201	0.00196	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—liver cancer	0.000196	0.00191	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—liver cancer	0.000193	0.00188	CcSEcCtD
Tapentadol—Diarrhoea—Epirubicin—liver cancer	0.000187	0.00182	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—liver cancer	0.000186	0.00181	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—liver cancer	0.000181	0.00177	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—liver cancer	0.000181	0.00176	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—liver cancer	0.000179	0.00174	CcSEcCtD
Tapentadol—Vomiting—Epirubicin—liver cancer	0.000174	0.00169	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—liver cancer	0.000173	0.00169	CcSEcCtD
Tapentadol—Rash—Epirubicin—liver cancer	0.000172	0.00168	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—liver cancer	0.000172	0.00168	CcSEcCtD
Tapentadol—Headache—Epirubicin—liver cancer	0.000171	0.00167	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—liver cancer	0.000167	0.00163	CcSEcCtD
Tapentadol—Nausea—Epirubicin—liver cancer	0.000162	0.00158	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—liver cancer	0.000161	0.00157	CcSEcCtD
Tapentadol—Rash—Doxorubicin—liver cancer	0.000159	0.00155	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—liver cancer	0.000159	0.00155	CcSEcCtD
Tapentadol—Headache—Doxorubicin—liver cancer	0.000158	0.00154	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—liver cancer	0.00015	0.00146	CcSEcCtD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	2.76e-05	0.000169	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTM1—liver cancer	2.76e-05	0.000169	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTA2—liver cancer	2.75e-05	0.000168	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CD—liver cancer	2.75e-05	0.000168	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL2—liver cancer	2.69e-05	0.000165	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TERT—liver cancer	2.68e-05	0.000164	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTA1—liver cancer	2.66e-05	0.000162	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CSF2—liver cancer	2.64e-05	0.000161	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—RAF1—liver cancer	2.63e-05	0.000161	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NAT2—liver cancer	2.63e-05	0.00016	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP1A1—liver cancer	2.62e-05	0.00016	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—H2AFX—liver cancer	2.6e-05	0.000159	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—IL2—liver cancer	2.6e-05	0.000159	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTA4—liver cancer	2.6e-05	0.000159	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTA4—liver cancer	2.58e-05	0.000157	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CB—liver cancer	2.57e-05	0.000157	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTA2—liver cancer	2.53e-05	0.000155	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.53e-05	0.000154	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PRKCE—liver cancer	2.52e-05	0.000154	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CG—liver cancer	2.52e-05	0.000154	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALDOB—liver cancer	2.52e-05	0.000154	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	2.52e-05	0.000154	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTA2—liver cancer	2.51e-05	0.000153	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CD—liver cancer	2.49e-05	0.000152	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KDR—liver cancer	2.45e-05	0.00015	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTA1—liver cancer	2.44e-05	0.000149	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—MTHFR—liver cancer	2.44e-05	0.000149	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK14—liver cancer	2.44e-05	0.000149	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PPARG—liver cancer	2.43e-05	0.000149	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTA1—liver cancer	2.42e-05	0.000148	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NAT2—liver cancer	2.42e-05	0.000148	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CRABP1—liver cancer	2.4e-05	0.000147	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NAT2—liver cancer	2.4e-05	0.000146	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CB—liver cancer	2.39e-05	0.000146	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARA—liver cancer	2.39e-05	0.000146	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ESR1—liver cancer	2.39e-05	0.000146	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF2—liver cancer	2.39e-05	0.000146	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—F2—liver cancer	2.36e-05	0.000144	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL2—liver cancer	2.36e-05	0.000144	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TERT—liver cancer	2.35e-05	0.000144	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALDOB—liver cancer	2.32e-05	0.000141	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.3e-05	0.000141	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALDOB—liver cancer	2.3e-05	0.00014	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—APC—liver cancer	2.26e-05	0.000138	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CG—liver cancer	2.26e-05	0.000138	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CSF2—liver cancer	2.23e-05	0.000136	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—RAF1—liver cancer	2.23e-05	0.000136	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CD—liver cancer	2.22e-05	0.000135	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CRABP1—liver cancer	2.21e-05	0.000135	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—H2AFX—liver cancer	2.2e-05	0.000134	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—IL2—liver cancer	2.2e-05	0.000134	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CRABP1—liver cancer	2.19e-05	0.000134	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ALB—liver cancer	2.19e-05	0.000134	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CB—liver cancer	2.17e-05	0.000133	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.16e-05	0.000132	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KDR—liver cancer	2.15e-05	0.000131	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.15e-05	0.000131	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK14—liver cancer	2.14e-05	0.000131	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—BRAF—liver cancer	2.13e-05	0.00013	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HPGDS—liver cancer	2.1e-05	0.000128	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ESR1—liver cancer	2.1e-05	0.000128	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.09e-05	0.000127	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—F2—liver cancer	2.07e-05	0.000127	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CG—liver cancer	2.05e-05	0.000125	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL2—liver cancer	2e-05	0.000122	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TERT—liver cancer	1.99e-05	0.000121	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CD—liver cancer	1.99e-05	0.000121	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APC—liver cancer	1.98e-05	0.000121	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CG—liver cancer	1.98e-05	0.000121	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARG—liver cancer	1.98e-05	0.000121	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.97e-05	0.00012	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CA—liver cancer	1.97e-05	0.00012	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SERPINE1—liver cancer	1.97e-05	0.00012	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KRAS—liver cancer	1.95e-05	0.000119	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CB—liver cancer	1.93e-05	0.000118	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HPGDS—liver cancer	1.93e-05	0.000118	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HPGDS—liver cancer	1.91e-05	0.000117	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.9e-05	0.000116	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.9e-05	0.000116	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.88e-05	0.000115	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PSMA4—liver cancer	1.87e-05	0.000114	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PSMD10—liver cancer	1.87e-05	0.000114	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—BRAF—liver cancer	1.86e-05	0.000114	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GOT2—liver cancer	1.82e-05	0.000111	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KDR—liver cancer	1.82e-05	0.000111	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK14—liver cancer	1.81e-05	0.00011	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CD—liver cancer	1.8e-05	0.00011	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—liver cancer	1.79e-05	0.000109	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—liver cancer	1.78e-05	0.000109	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RAF1—liver cancer	1.77e-05	0.000108	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ESR1—liver cancer	1.77e-05	0.000108	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—F2—liver cancer	1.75e-05	0.000107	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CD—liver cancer	1.74e-05	0.000106	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.73e-05	0.000106	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MTOR—liver cancer	1.73e-05	0.000106	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CB—liver cancer	1.73e-05	0.000106	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—liver cancer	1.73e-05	0.000105	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SERPINE1—liver cancer	1.72e-05	0.000105	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PSMA4—liver cancer	1.72e-05	0.000105	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PSMD10—liver cancer	1.72e-05	0.000105	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP2E1—liver cancer	1.71e-05	0.000105	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.71e-05	0.000105	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—liver cancer	1.71e-05	0.000104	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PSMA4—liver cancer	1.71e-05	0.000104	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PSMD10—liver cancer	1.71e-05	0.000104	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CG—liver cancer	1.68e-05	0.000102	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APC—liver cancer	1.68e-05	0.000102	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GOT2—liver cancer	1.67e-05	0.000102	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GOT2—liver cancer	1.66e-05	0.000101	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.66e-05	0.000101	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—liver cancer	1.65e-05	0.000101	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1B—liver cancer	1.63e-05	9.93e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—liver cancer	1.61e-05	9.82e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYCS—liver cancer	1.6e-05	9.78e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—liver cancer	1.59e-05	9.73e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—liver cancer	1.59e-05	9.72e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—liver cancer	1.58e-05	9.67e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BRAF—liver cancer	1.58e-05	9.62e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2E1—liver cancer	1.57e-05	9.62e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GGT1—liver cancer	1.57e-05	9.6e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GOT1—liver cancer	1.57e-05	9.6e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CB—liver cancer	1.57e-05	9.59e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—liver cancer	1.57e-05	9.58e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2E1—liver cancer	1.56e-05	9.53e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RAF1—liver cancer	1.56e-05	9.5e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—liver cancer	1.55e-05	9.47e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUN—liver cancer	1.55e-05	9.45e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CTNNB1—liver cancer	1.54e-05	9.38e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MTOR—liver cancer	1.52e-05	9.28e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CB—liver cancer	1.52e-05	9.28e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.51e-05	9.23e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—liver cancer	1.51e-05	9.2e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1A—liver cancer	1.5e-05	9.17e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CD—liver cancer	1.47e-05	9e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYCS—liver cancer	1.47e-05	9e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK8—liver cancer	1.46e-05	8.95e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—liver cancer	1.46e-05	8.92e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYCS—liver cancer	1.46e-05	8.92e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—liver cancer	1.46e-05	8.91e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SERPINE1—liver cancer	1.46e-05	8.9e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—liver cancer	1.45e-05	8.86e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GGT1—liver cancer	1.45e-05	8.83e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GOT1—liver cancer	1.45e-05	8.83e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—liver cancer	1.44e-05	8.81e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GGT1—liver cancer	1.43e-05	8.75e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GOT1—liver cancer	1.43e-05	8.75e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1B—liver cancer	1.43e-05	8.71e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—liver cancer	1.41e-05	8.62e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—liver cancer	1.41e-05	8.61e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—liver cancer	1.4e-05	8.54e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—liver cancer	1.4e-05	8.52e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMOX1—liver cancer	1.39e-05	8.5e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—liver cancer	1.39e-05	8.48e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—liver cancer	1.36e-05	8.31e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUN—liver cancer	1.36e-05	8.29e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—liver cancer	1.35e-05	8.26e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CTNNB1—liver cancer	1.35e-05	8.23e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—liver cancer	1.34e-05	8.18e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—liver cancer	1.33e-05	8.09e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—liver cancer	1.32e-05	8.07e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1A—liver cancer	1.32e-05	8.04e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAF1—liver cancer	1.32e-05	8.03e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—liver cancer	1.3e-05	7.93e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—liver cancer	1.3e-05	7.92e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—liver cancer	1.29e-05	7.86e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK8—liver cancer	1.28e-05	7.84e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CB—liver cancer	1.28e-05	7.84e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MTOR—liver cancer	1.28e-05	7.84e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—liver cancer	1.28e-05	7.82e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMOX1—liver cancer	1.28e-05	7.82e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMOX1—liver cancer	1.27e-05	7.75e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—liver cancer	1.24e-05	7.6e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFB1—liver cancer	1.24e-05	7.58e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A1—liver cancer	1.23e-05	7.51e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—liver cancer	1.23e-05	7.49e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1B—liver cancer	1.21e-05	7.36e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—liver cancer	1.19e-05	7.29e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—liver cancer	1.19e-05	7.28e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—liver cancer	1.19e-05	7.24e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—liver cancer	1.18e-05	7.22e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—liver cancer	1.18e-05	7.21e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—liver cancer	1.18e-05	7.2e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—liver cancer	1.18e-05	7.2e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—liver cancer	1.17e-05	7.17e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—liver cancer	1.17e-05	7.17e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—liver cancer	1.15e-05	7.02e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—liver cancer	1.15e-05	7.02e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUN—liver cancer	1.15e-05	7.01e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—MTHFR—liver cancer	1.15e-05	7e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CTNNB1—liver cancer	1.14e-05	6.95e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A1—liver cancer	1.13e-05	6.91e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARA—liver cancer	1.12e-05	6.87e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A1—liver cancer	1.12e-05	6.85e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—liver cancer	1.12e-05	6.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1A—liver cancer	1.11e-05	6.79e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—liver cancer	1.09e-05	6.66e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFB1—liver cancer	1.09e-05	6.65e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK8—liver cancer	1.09e-05	6.63e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—liver cancer	1.08e-05	6.61e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—liver cancer	1.06e-05	6.45e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—MTHFR—liver cancer	1.05e-05	6.44e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—MTHFR—liver cancer	1.05e-05	6.38e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARA—liver cancer	1.03e-05	6.32e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARA—liver cancer	1.03e-05	6.26e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—liver cancer	1.02e-05	6.24e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.01e-05	6.17e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—liver cancer	1.01e-05	6.16e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—liver cancer	1e-05	6.12e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—liver cancer	9.92e-06	6.06e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—liver cancer	9.77e-06	5.97e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CG—liver cancer	9.63e-06	5.88e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—liver cancer	9.62e-06	5.88e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—liver cancer	9.57e-06	5.85e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—liver cancer	9.35e-06	5.71e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARG—liver cancer	9.3e-06	5.68e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—liver cancer	9.26e-06	5.66e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—liver cancer	9.22e-06	5.63e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	9.21e-06	5.63e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFB1—liver cancer	9.2e-06	5.62e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—liver cancer	8.96e-06	5.47e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CG—liver cancer	8.86e-06	5.41e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CG—liver cancer	8.78e-06	5.36e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—liver cancer	8.63e-06	5.27e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—liver cancer	8.57e-06	5.23e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARG—liver cancer	8.55e-06	5.22e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—liver cancer	8.52e-06	5.2e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARG—liver cancer	8.48e-06	5.18e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CD—liver cancer	8.47e-06	5.17e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—liver cancer	8.36e-06	5.11e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—liver cancer	8.2e-06	5.01e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—liver cancer	7.83e-06	4.78e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—liver cancer	7.82e-06	4.78e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CD—liver cancer	7.79e-06	4.76e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CD—liver cancer	7.72e-06	4.72e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—liver cancer	7.69e-06	4.7e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—liver cancer	7.62e-06	4.66e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—liver cancer	7.57e-06	4.63e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—liver cancer	7.57e-06	4.62e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CB—liver cancer	7.38e-06	4.51e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—liver cancer	7.24e-06	4.42e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—liver cancer	6.93e-06	4.23e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CB—liver cancer	6.79e-06	4.15e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CB—liver cancer	6.73e-06	4.11e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—liver cancer	6.4e-06	3.91e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—liver cancer	4.5e-06	2.75e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—liver cancer	4.14e-06	2.53e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—liver cancer	4.1e-06	2.51e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—liver cancer	3.68e-06	2.24e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—liver cancer	3.38e-06	2.06e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—liver cancer	3.35e-06	2.05e-05	CbGpPWpGaD
